Ketamine G.L. Pharma

Ketamine, the active ingredient in Ketamine G.L. Pharma, is a dissociative anesthetic presented as an injectable solution for intravenous use. It is employed for induction of anesthesia, analgesia, sedation, and treatment‑resistant depression in appropriate patients.

GNH USA supplies Ketamine G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketamine acts on the central nervous system as an NMDA‑receptor antagonist, providing dissociative anesthesia and analgesia.

Induction of anesthesia: produces rapid loss of consciousness for surgical procedures. Analgesia: provides potent pain relief during and after surgery. Sedation: offers controlled sedation for diagnostic or therapeutic interventions. Treatment‑resistant depression: used under specialist supervision to alleviate depressive symptoms when other therapies have failed.

Ketamine may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness. - Nausea and vomiting. - Increased heart rate or blood pressure. - Visual disturbances or feeling detached from reality.

Serious or Rare Side Effects: - Respiratory depression requiring airway support. - Severe hypertension or cardiac arrhythmias. - Emergence reactions such as vivid dreams or agitation. - Allergic reactions including rash, bronchospasm, or anaphylaxis.

Ketamine requires careful monitoring and specific safety measures.

Cardiovascular monitoring: observe patients with hypertension or cardiac disease closely. Respiratory monitoring: ensure airway protection and oxygenation during administration. Psychiatric evaluation: avoid use in patients with active psychosis or severe mental illness. Drug interaction review: assess concomitant CNS depressants and sympathomimetics. Store at ambient temperature: keep in original container, protect from light and moisture.

Ketamine can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent NMDA antagonists (e.g., dextromethorphan) may potentiate effects. - Combination with MAO inhibitors can increase risk of severe hypertension. - Potent CYP450 inhibitors may raise plasma ketamine levels.

Moderate Interactions (Monitor Closely): - Benzodiazepines may reduce anesthetic potency. - Opioids can produce additive respiratory depression. - Sympathomimetic agents may exacerbate hypertension. - Certain anticholinergics may affect heart rate control.